Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BCAB | 8-K | bearish | 8/10 | BioAtla received final delisting notice from Nasdaq on August 26, 2026, after the Nasdaq Listing Council affirmed the He | Aug 28, 2026 |
| RADX | 6-K | bearish | 8/10 | Radiopharm Theranostics filed its preliminary final report for FY2026 (year ended June 30, 2026), showing a sharp deteri | Aug 28, 2026 |
| IMRN | 6-K | neutral | 4/10 | Immuron Ltd reported FY26 preliminary results showing revenue up 5.9% to A$7.7M and net loss improved 26.4% to A$3.8M. C | Aug 28, 2026 |
| BLRX | PRESS-RELEASE | bearish | 6/10 | BioLineRx announced a $3.75M registered direct offering and concurrent private placement, selling 1,348,921 ADSs at $2.7 | Aug 28, 2026 |
| XRTX | 6-K | mixed | 5/10 | XORTX terminated its $2.5M investor relations agreement with IR Agency LLC and received a full refund of the funds, post | Aug 28, 2026 |
| PLUR | 8-K | bearish | 7/10 | Pluri Inc. raised approximately $2.98 million in net proceeds through a registered direct offering and concurrent privat | Aug 28, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a Form 6-K on August 28, 2026, submitting an application for quotation of securities (ATH) o | Aug 28, 2026 |
| KALA | 8-K | bearish | 8/10 | KALA BIO received a delisting notice from Nasdaq on August 27, 2026, because its stock closed below $1.00 for 30 consecu | Aug 28, 2026 |
| IBIO | PRESS-RELEASE | neutral | 4/10 | iBio reported fiscal year 2026 results with revenue of $0.1M (down from $0.4M) and a net loss of -$33.0M, wider than the | Aug 28, 2026 |
| TEVA | PRESS-RELEASE | bullish | 6/10 | Teva announced a stalking-horse bid to acquire BioXcel Therapeutics' IGALMI (dexmedetomidine sublingual film) and relate | Aug 28, 2026 |
| PYXS | EFFECT | bearish | 6/10 | Pyxis Oncology's S-3 shelf registration (File No. 333-298461) became effective on August 27, 2026, allowing the company | Aug 28, 2026 |
| ORKA | EFFECT | bearish | 6/10 | Oruka Therapeutics' S-3 shelf registration (File No. 333-298488) became effective on August 27, 2026. This allows the co | Aug 28, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a Form 6-K with an Appendix 4G, a routine corporate governance disclosure required by the AS | Aug 28, 2026 |
| KZIA | 6-K, 424B5 | bearish | 5/10 | Kazia Therapeutics filed a 6-K and a 424B5 prospectus supplement on August 28, 2026, reducing the maximum aggregate offe | Aug 28, 2026 |
| KZIA | 424B5 | neutral | 4/10 | Kazia Therapeutics filed a 424B5 prospectus supplement reducing the maximum aggregate offering price of ADSs available u | Aug 28, 2026 |
| SAFX | EFFECT | bearish | 8/10 | The SEC declared effective XCF Global's S-1 registration statement (File No. 333-291024) on August 27, 2026, covering th | Aug 28, 2026 |
| QNRX | PRESS-RELEASE | bearish | 7/10 | Quoin Pharmaceuticals announced a private placement raising up to ~$50M in gross proceeds, with ~$30.8M upfront from iss | Aug 28, 2026 |
| BTAI | PRESS-RELEASE | bearish | 9/10 | BioXcel Therapeutics announced it has entered into a stalking horse asset sale agreement with Teva Pharmaceuticals for s | Aug 28, 2026 |
| IMRN | PRESS-RELEASE | neutral | 4/10 | Immuron reported FY26 results with record sales of A$7.7M (+6% YoY) and net profit improvement of A$1.4M. The company hi | Aug 28, 2026 |
| QNRX | PRESS-RELEASE | bullish | 7/10 | Quoin Pharmaceuticals announced positive interim Phase 2/3 results for QRX003 in Netherton Syndrome: 4 of 6 patients (66 | Aug 28, 2026 |
| BMRA | CLUSTER | mixed | 6/10 | Biomerica insiders, including the CEO and Executive Vice Chairman, made open-market purchases totaling $158K on August 2 | Aug 28, 2026 |
| MEDP | CLUSTER | neutral | 3/10 | Four Medpace insiders, including the CEO, CFO, and two directors, sold a total of $10.0M in shares over a one-week windo | Aug 28, 2026 |
| QTTB | CLUSTER | neutral | 2/10 | Q32 Bio CEO and CFO sold a combined $229K in open-market sales on August 25, 2026, at $16.56 per share. The total value | Aug 28, 2026 |
| TWST | CLUSTER | neutral | 4/10 | A cluster of insider selling at Twist Bioscience, led by CEO Emily Leproust selling ~$6.3M in open-market transactions o | Aug 28, 2026 |
| CSTL | CLUSTER | neutral | 4/10 | Two C-suite insiders at Castle Biosciences sold a combined $498K in open-market transactions over two days, with the COO | Aug 28, 2026 |
| CRL | CLUSTER | neutral | 3/10 | Two CRL insiders sold a total of ~$763K in open-market shares over the past week, while Director James C. Foster exercis | Aug 28, 2026 |
| CORT | CLUSTER | neutral | 2/10 | Two Corcept Therapeutics insiders sold a total of ~$788K in shares over a week, with the bulk ($740K) from Sean Maduck ( | Aug 28, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined ~$388K in open-market UTHR shares over the past week, with Roth | Aug 28, 2026 |
| MNPR | CLUSTER | neutral | 3/10 | Two Monopar Therapeutics directors sold a total of $144K in open-market sales over a two-day window, with Kim Tsuchimoto | Aug 27, 2026 |
| GILD | CLUSTER | neutral | 2/10 | Two GILD directors sold a combined $926K in open-market sales over a one-week window. Director Anthony Welters executed | Aug 27, 2026 |